Indazole compounds, their pharmaceutically acceptable salts, prodrugs or pharmaceutically active metabolites, pharmaceutical compositions, method of treating diseases or dysfunctions mediated by the inhibition of a kinase complex, method of treating mammalian diseases mediated by kinase activity, method of modulation or inhibition of the activity of a protein kinase receptor, method of treatment of unhealthy condition or dysfunction associated with uncontrolled cell proliferation, pharmaceutical composition for the treatment of unhealthy condition associated with uncontrolled cell proliferation and method of treatment of unhealthy condition or associated dysfunction to uncontrolled cell proliferation

摘要

"INDAZOL COMPOUNDS, ITS PHARMACEUTICALLY ACCEPTABLE SALES, PHARMACEUTICALLY ACTIVE PRO-DRUGS OR METABOLITES, PHARMACEUTICAL COMPOSITIONS, METHOD OF TREATING DISEASES OR DYSFUNCTIONS MEASURED IN DISEASE MEASURES, DISEASE MEASURES, DISEASE MEASURES METHOD OF MODULATION OR INHIBITION OF THE ACTIVITY OF A PROTEIN KINASE RECEIVER, METHOD OF TREATING SICK STATE OR DYSFUNCTION ASSOCIATED WITH UNCONTROLLED CELL PROLIFERATION, PHARMACEUTICAL COMPOSITION OF THE TREATMENT OF TREATMENT OF TREATMENT OF TREATMENT OF TREATMENT OF TREATMENT OF TREATMENTAL TREATMENT. ASSOCIATED WITH UNCONTROLLED CELLULAR PROLIFERATION ". Indazole compounds that modulate and / or inhibit cell proliferation, such as protein kinase activity, have been described. These compounds and pharmaceutical compositions containing them are capable of mediating, for example, kinase-dependent diseases to modulate and / or inhibit unwanted cell proliferation. The present invention also relates to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and cancer treatment methods, as well as other unhealthy conditions associated with cell proliferation and / or unwanted angiogenesis, such as diabetic retinopathy, neovascular glaucoma, arthritis rheumatoid and psoriasis, by administering effective amounts of these compounds.